CNBC Pro Talks: Chart analyst Katie Stockton on locating successful shares in a getting rid of market

CNBC Pro Talks: Chart analyst Katie Stockton on locating successful shares in a getting rid of market


Share

CNBC Pro

Fairlead Procedures founder and chart analyst Katie Stockton shares what she is looking at on the specialized aspect of the market. She also goes in-depth on the stocks she sees foremost the way both up or down.



Supply

CNBC’s The China Connection newsletter: China’s K-visa plans spark worries of a talent flood
World

CNBC’s The China Connection newsletter: China’s K-visa plans spark worries of a talent flood

This report is from this week’s CNBC’s The China Connection newsletter, which brings you insights and analysis on what’s driving the world’s second-largest economy. You can subscribe here. The big story Immigration anxieties and a challenging job market have sparked an online backlash over China’s latest attempt at attracting global talent — a new visa program […]

Read More
India holds rates steady at 5.5% in line with forecast as central bank assesses earlier cuts
World

India holds rates steady at 5.5% in line with forecast as central bank assesses earlier cuts

India’s central bank kept its policy rate unchanged at 5.5% Wednesday, in line with the expectations of economists polled by Reuters, as it assessed the impact of earlier cuts. Inflation moderated significantly in the first quarter, but growth could decelerate in the second half of the financial year due to global trade uncertainties, said Sanjay […]

Read More
CNBC’s UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
World

CNBC’s UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

This report is from this week’s CNBC’s UK Exchange newsletter. Like what you see? You can subscribe here. The dispatch There is an old British saying about buses: you wait ages for one and then two arrive at once. Pharmaceuticals analysts experienced something similar on Monday as the big two U.K. drugmakers — GSK and AstraZeneca — […]

Read More